10X Genomics Inc Cash Flow-to-Debt Ratio
10X Genomics Inc cash flow-to-debt ratio. 10X Genomics Inc (TXG) has a Cash Flow-to-Debt Ratio of 0.08x as of June 2026, meaning its operating cash flow of $16.97 Million could theoretically repay 0% of its total liabilities ($204.52 Million) in one year. Check TXG cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of 10X Genomics Inc (2017–2025)
Cash flow-to-debt ratio of 10X Genomics Inc from 2017 to 2025. Historical debt coverage capacity for 10X Genomics Inc across 9 annual periods. Check TXG total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
10X Genomics Inc Cash Flow-to-Debt Ratio by Year (2017–2025)
10X Genomics Inc cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for 10X Genomics Inc. For the full cash flow conversion analysis, see 10X Genomics Inc operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.56x | $136.05 Million | $245.04 Million | ▲ +1637.2% |
| 2024 | 0.03x | $6.66 Million | $208.50 Million | ▲ +147.1% |
| 2023 | -0.07x | $-15.20 Million | $224.10 Million | ▲ +55.0% |
| 2022 | -0.15x | $-33.61 Million | $223.24 Million | ▼ -41.8% |
| 2021 | -0.11x | $-21.37 Million | $201.26 Million | ▲ +90.7% |
| 2020 | -1.15x | $-217.90 Million | $190.27 Million | ▼ -714.6% |
| 2019 | 0.19x | $34.63 Million | $185.84 Million | ▲ +184.0% |
| 2018 | -0.22x | $-76.41 Million | $344.30 Million | ▼ -290.2% |
| 2017 | -0.06x | $-10.70 Million | $188.12 Million | — |